Drug Eluting Stent Market to Reach USD 9.58 Billion by 2026; Launch of Bioabsorbable Polymers as Result of Continuous R&D will Aid in Expansion of the Market

The global drug eluting stent (DES) market size is projected to reach USD 9.58 billion by 2026, owing to the increasing prevalence of cardiovascular diseases worldwide. Drug eluting stent are a coronary or peripheral stent that is located in a narrowed, coronary artery or diseased peripheral and slowly releases a drug to block the proliferation of the cell. This information is provided in a recently published report by Fortune Business Insights™ titled, “Drug Eluting Stent (DES) Market Size, Share & Industry Analysis, By Type (Coronary Stenting, and Peripheral Stenting), By Scaffold (Cobalt-Chromium, Platinum-Chromium, Nitinol and Others), By Drug (Sirolimus, Paclitaxel, Zotarolimus, Everolimus, and Others), By End User (Hospitals, and Specialty Clinics), and Regional Forecast, 2019-2026.” According to this report, the market value stood at USD 5.71 billion and will exhibit 6.6% between 2019 to 2026.

Supraflex Cruz received CE Mark Approval for Being Highly Deliverable Stent

The next-generation Supraflex Stent System, introduced into the market by Sahajanand Medical Technologies (SMT), announced the CE mark it received for helping physicians get access to the toughest lesions easily without exposing the patient to any harmful radiation. Mr. Ganesh Sabat, the CEO of SMT, says, “We are aiming to offer this stent to thousands of patients who cannot opt for PCI (percutaneous coronary intervention) due to their complex anatomies and offer it across Europe as well.” Supraflex Cruz offers the following advantages:

• Less procedure time and less intake of harmful radiation
• Fewer complications at the time of the procedure due to better delivery of the stent
• Skipping bypass surgery for patients, thus saving lives.

Other companies are also planning to develop innovative stents to improve the quality of life of patients. Such innovations are likely to aid in the expansion of the market in the long run.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/drug-eluting-stent-des-market-102612

 Increasing Prevalence of Peripheral Arterial Diseases will Drive Market

The rising prevalence of cardiovascular diseases (CVDs) is a significant factor in promoting the drug eluting stent market growth. This, coupled with the increasing cases of peripheral arterial diseases (PADs), is a considerable factor aiding in the expansion of the market during the forecast period. Besides this, the rise in government initiatives in the form of awareness programs, improved healthcare infrastructure, and reimbursement policies are expected to boost the market in the coming years. Furthermore, currently trending biodegradable polymer-based stents are gaining popularity and are expected to add impetus to the market in the long run.

On the flip side, the increasing number of product recalls may pose a significant threat to the market in the coming years. Nevertheless, massive investments in research and development of novel therapeutics will help create lucrative growth opportunities for the market in the long run.

Consolidated Nature of Market to Intensify Market Competition

The global drug eluting stent market is consolidated in nature with the presence of many players at the entry-level, and with sizes varying from small, medium to large. These companies are launching new products of different sizes to stand out in the market competition and earn high shares. However, companies such as Boston Scientific Corporation, Medtronic, and Abbott are holding more than 50% DES market share.  Other players are emphasizing on mergers and acquisitions, company collaborations, research and development, and different strategies to attract high drug eluting stent market revenue in the years to come.

Notable Industry Developments of Drug Eluting Stent Market are the following:

• February 2019 – FDA approved iOrsiro ultrathin drug eluting stent designed by BIOTRONIK for use in percutaneous coronary intervention procedures.

List of Significant Drug Eluting Stents Market Manufacturers include:

• Terumo Corporation
• Boston Scientific Corporation
• Medtronic
• Microport Scientific Corporation
• Abbott
• Biotronik
• Other players

Further Report Findings

• North America emerged significant share in the market and earned a drug eluting stent market share of USD 1.76 billion in 2018. This is owing to the increasing prevalence of cardiovascular diseases and the growing demand for biodegradable polymer-based stents.
• In terms of segmentation by stenting, the coronary stenting segment will witness significant growth in the coming years on account of the increasing prevalence of peripheral vascular diseases worldwide.

Global Drug Eluting Stent Market is segmented into: